Quantcast

Latest Experimental cancer treatments Stories

2014-07-28 10:33:11

Dartmouth-Hitchcock Norris Cotton Cancer Center Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading. One pioneering approach, discussed in a review article published this week in WIREs Nanomedicine and Nanobiotechnology, uses...

2014-07-10 08:27:19

SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today a publication that reviews data from the company's oncolytic immunotherapy program, including its lead product Pexa-Vec. Additionally, the publication outlines the rationale for combination therapy with other cancer immunotherapies, such as...

2014-06-20 08:23:15

BUSAN, South Korea and SAN FRANCISCO, June 20, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that the company will make a presentation next week at the BIO Business Forum, which is a part of the 2014 BIO International Convention being held in San Diego, CA. David McDonald, chief business officer of SillaJen, will present on Tuesday, June 24, 2014 at 2:15...

2014-06-19 16:26:16

Merger Creates Global Leader In Oncolytic Immunotherapy BUSAN, South Korea and SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that it has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics. SillaJen's lead product Pexa-Vec (formerly JX-594) demonstrated an overall survival...

2014-06-18 04:21:16

Unique Immuno-Oncolytic Therapy Gets Closer to a More Effective, Safer Cancer Treatment and Potential Cure CLEVELAND, June 18, 2014 /PRNewswire-USNewswire/ --­­ Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill...

2014-06-17 11:02:54

Ohio State University Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Viruses that are designed to kill cancer cells – oncolytic viruses – have shown promise in clinical trials for the...

2014-05-20 08:31:42

CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org. The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. "Treatment...

herpes virus attack a brain tumor cell
2014-05-18 03:00:47

Harvard Stem Cell Institute (HSCI) Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat. The work, led by Khalid...

2014-04-16 14:11:59

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy. Wei Chen, professor of physics and co-director of UT Arlington's Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine complex created in his lab when he discovered unexplained decreases in its luminescence, or light emitting power, over a...

2014-04-14 12:33:03

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related